“Risk is a lens, not a leash. Once teams see what truly threatens patients and processes, the busywork falls away, and quality gets sharper,” said Sindhuri Korrapati, a senior supervisor for software quality, describing the recent shift from computer system validation to risk-based computer software assurance in life sciences and digital systems.
Changes in regulated industries often arrive quietly, under the cover of paperwork and long policy reviews. However, the transition from Computer System Validation (CSV) to Computer Software Assurance (CSA) marked a huge shift: diminished rote documentation, sharpened evidence, and new clarity about what can actually impact patient care or compromise the quality system.
This pivot reshaped validation for production and quality system software under 21 CFR Part 820, aligning compliance with learner processes that focus on actual patient and process risks. Korrapati stands on that frontline, translating evolving regulations into day-to-day discipline across a vast portfolio of GxP-relevant applications, promoting a culture that distinguishes between busywork and genuine assurance.
Rethinking Assurance: CSA in Context
CSA’s heart is proportionality: align validation effort with the importance and risk of each function, emphasizing real-world consequences over ritual completeness. Heavy scripted tests now belong to high-risk workflows, while digital logs, vendor data, and exploratory tests satisfy less critical assurance needs. With CSA, compliance is a matter of discernment, not routine, and Korrapati’s teams now spend more time mapping workflows and interrogating logic, rather than preparing binders of documentation.
Sindhuri’s own words sum up the shift: “You start by redrawing the map—what features directly touch production controls, what supports the quality system, what’s just business IT—and then you route assurance energy to the red zones,” she notes, describing how every new application deployment begins with hard choices about what matters most and what can be documented with digital evidence rather than costly test campaigns. The result is a quicker turnaround on quality and a greater focus on consequential risks.
The Practitioner’s Challenge
Korrapati’s view is uncommonly broad, and her challenge is practical: not just flipping CSV to CSA, but creating repeatable frameworks that allow teams to defend every assurance decision under audit, scoping intended use, risk, and evidence in ways that withstand scrutiny.
“If you can’t explain why a test matters for the patient or the product, it probably doesn’t,” she tells her teams, urging a litmus test for assurance activities. Her published piece, Trust But Verify, extends these principles to the emerging field of AI validation in GxP, where success depends less on generic best practices and more on tightly linking data integrity, model logic, and outcome monitoring to the demands of the regulated process.
Robotics: Raising Quality’s Game
Robotics companies are digital to the core, with every function, from production to complaint review, now piped through software and analytics. For leaders like Korrapati, validating that estate means translating regulatory guidance into clear rules about what triggers assurance: “If a system’s output informs a release, calibration, CAPA, or a training credential, it’s in scope, and it has to be reliable,” she states. That view demands constant vigilance around data integrity, traceability, and audit logs.
Exploratory testing, automated checks, and vendor evidence now combine to reduce the time required for validating low-risk features, freeing teams to conduct deeper dives on functions whose failure could compromise quality or compliance. In this landscape, assurance is not just a requirement; it is a living system that evolves as products and processes change.
The Numbers that Matter
The last year has brought conversations about CSA’s practicalities, not its theory: how much documentation is enough, when vendor data is adequate, and how teams can scale controls for AI-enabled workflows entering the regulatory perimeter. Best practices now support the use of audit trails, digital logs, and automated testing to satisfy requirements, thereby minimizing the impact on lower-risk areas. As robotic surgery advances, so does the cost of poor assurance: delays, compliance setbacks, and even hidden data errors that emerge only under audit or in the event of failure.
Korrapati keeps her metrics tight: “We measure where it helps decisions,” she explains, noting that her VBA automation project cut complaint review cycle times without losing essential human oversight. Automations like this, if they inform regulated decisions, must themselves be validated proportionally—showing reliability, security, and auditability in direct relation to impact.
AI and the New Assurance Frontier
Korrapati’s article on AI in pharma’s GxP processes frames the issue practically: validate not for show, but for real-world impact. Data governance and model integrity are only relevant if they preserve patient safety and GxP outcomes. Test cases must be chosen to reflect actual risks, and monitoring must be established as a continual assurance that triggers action as soon as changes indicate potential harm. In short: “trust but verify,” but only where the risk lies.
FDA leaves room for fit-for-purpose solutions. When AI tools support manufacturing or QMS, but do not touch medical devices directly, CSA gives teams latitude to decide how much assurance is enough, so long as every decision is linked to process risk and intended use. The rise of AI adds pressure for clarity, not more paperwork.
A Cautious Viewpoint
Still, as one veteran compliance consultant noted, “Risk is not a get-out-of-validation card,” cautioning that some teams might use CSA as cover to under-test, relying on vendors and low classifications to skip essential work. The FDA’s rubric is designed to block this, requiring upfront scoping and appropriate evidence, digital or scripted, for every regulated feature. Korrapati addresses this tension head-on: “You can’t skip the scoping; you have to put the map on the wall,” she insists, describing hands-on sessions where intended use, risk, and evidence plans are hammered out before documents are filed. In CSA’s best form, quality actually increases, not decreases, because the work is focused on reality.
Community and Conferences
The CSA movement now spreads through industry events, SQA chapters, and conferences like MARSQA, with Korrapati herself presenting cases and lessons learned throughout 2025. These forums highlight the practical aspects of assurance, including checklists, decision trees, case studies, and guidance on integrating vendor data with in-house processes. Shared wisdom will shape the early adoption of CSA, especially as AI-enabled tools enter the quality map.
The professional network is essential: teams compare notes, share solutions, and track regulatory trends, with the common goal of maintaining high audit readiness and assurance that focuses on delivering the most value for patients and compliance.
Managerial Craft
Korrapati’s work does not promise disruption; it promises better allocation. Saved hours, clearer evidence, and more agile changes are possible when assurance is mapped to risk and constantly refreshed as business and technology move. “We’ve trained teams to narrate their choices: why this test, why this evidence, why this threshold,” she explains, treating every record as an argument, not just a box checked.
For fast-moving organizations, CSA supports dynamic change management, allowing deeper tests only for high-impact updates and freeing resources elsewhere. When digital systems evolve on a weekly basis, this flexibility spells the difference between stagnant innovation and responsive compliance.
Hard Realities
Even so, CSA is not automatic. Scoping requires discipline, and misclassifications can invite regulatory trouble. Vendor data is only as good as its alignment to actual use, meaning real-world validation cannot be shirked. AI introduces unique complexity: models evolve, data changes, and assurance must keep pace in real-time.
Korrapati’s last word on the topic returns to fundamentals: “The trick is to keep the chain unbroken, from intended use to evidence to operations, so when something changes, the map updates and the tests follow,” she states. This practical ethic, not grand transformation, powers resilience.
The Promise of Transformation
CSA’s promise is not in novelty, but precision: focus on consequential rigor, automate where possible, and use evidence in direct relation to risk. Leaders must direct talent to the places where patient and product outcomes hinge on software logic, and let documentation scale with actual impact. As robotic surgery and digital transformation deepen, assurance becomes the quiet foundation of all that follows.
In Korrapati’s words: “Quality is not a paperwork ritual. It is applied foresight, renewed with every change, because the risk never stays still.”
